Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) chief medical officer Dr Mark Bleakley tells Proactive they've engaged multinational contract development and manufacturing organisation (CDMO) Eurofins Scientific to manufacture the company’s topical ReneCann therapeutic cannabinoid formulation. ReneCann is a proprietary therapeutic developed to treat dermatological conditions caused by disorders of the immune system, including vitiligo, psoriasis and atopic dermatitis, otherwise known as eczema.
Incannex kicks off manufacture of skin therapeutics
